Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Danish pharmaceutical company Novo Nordisk (NVO) on Tuesday said that it has submitted an application to the European ...

Investing.com -- Novo Nordisk (NYSE: NVO) stock rose 1% after the company announced it has submitted an application to the ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

WeightWatchers on Tuesday named Dr. Kim Boyd as chief medical officer and said it was planning a new program to help women ...

Shares of Novo Nordisk (NYSE:NVO) rose 1% following news that the company has submitted an application to the European Medicines Agency (EMA) to approve a higher dose of its obesity treatment, Wegovy.

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Novo Nordisk (NVO) said on Monday that it will cease its partnership with Hims & Hers Health (NYSE: HIMS), ending the direct access to Wegovy, its weight loss drug, through NovoCare Pharmacy.

Novo Nordisk then opened direct channels to Wegovy through select telehealth providers, including Hims & Hers. However, Novo Nordisk said its internal review raised red flags.

Novo Nordisk in April said it would offer Wegovy through several telehealth companies such as Hims & Hers to expand access to the blockbuster injection now that it is no longer in short supply in ...